Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue

Brain

Volumn 136, Issue 7, 2013, Pages 2217-2227

  Ni, Ruiqing ^a   Gillberg, Per Göran ^a   Bergfors, Assar ^a   Marutle, Amelia ^a   Nordberg, Agneta ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; PIB; post mortem brain; amyloid fibril binding sites; amyloid imaging ligands

Indexed keywords

2 (4' METHYLAMINOPHENYL)BENZOTHIAZOLE; 2 [2 (2 DIMETHYLAMINOTHIAZOL 5 YL)ETHENYL] 6 (2[FLUORO]ETHOXY)BENZOXAZOLE; AMYLOID BETA PROTEIN; AV 1; AV 45; BF 227; BTA 1; FLORBETABEN; FLORBETAPIR F 18; PITTSBURGH COMPOUND B; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BINDING AFFINITY; BINDING SITE; BRAIN REGION; BRAIN TISSUE; CAUDATE NUCLEUS; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MALE; MOLECULAR IMAGING; NEUROIMAGING; PARIETAL CORTEX; PRIORITY JOURNAL; PROTEIN BINDING;

EID: 84879980176     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt142     Document Type: Article

References (75)

1. Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al. Binding characteristics of radiofluorinated 6-Dialkylamino-2- naphthylethylidene derivatives as positron emission tomography imaging probes for beta-Amyloid plaques in Alzheimer's disease. J Neurosci 2001; 21: RC189
2. Agdeppa ED, Kepe V, Liu J, Small GW, Huang SC, Petric A, et al. 2-Dialkylamino-6-Acylmalononitrile substituted naphthalenes (DDNP analogs): Novel diagnostic and therapeutic tools in Alzheimer's disease. Mol Imaging Biol 2003; 5: 404-17
3. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65: 1509-17
4. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: A multicentre phase 2 diagnostic study. Lancet Neurol 2011; 10: 424-35
5. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006; 66: 1837-44
6. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18F-AV-45: A PET agent for Abeta plaques in the brain. J Nucl Med 2009; 50: 1887-94
7. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-Amyloid pathology. JAMA 2011; 305: 275-83
8. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: A prospective cohort study. Lancet Neurol 2012; 11: 669-78
9. Cselenyi Z, Jonhagen ME, Forsberg A, Halldin C, Julin P, Schou M, et al. Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. J Nucl Med 2012; 53: 415-24
10. Driscoll I, Troncoso JC, Rudow G, Sojkova J, Pletnikova O, Zhou Y, et al. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol 2012; 124: 823-31
11. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer's disease: A new lexicon. Lancet Neurol 2010; 9: 1118-27
12. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129 (Pt 11): 2856-66
13. Fodero-Tavoletti MT, Brockschnieder D, Villemagne VL, Martin L, Connor AR, Thiele A, et al. In vitro characterization of [(18)F]-florbetaben, an Abeta imaging radiotracer. Nucl Med Biol 2012; 39: 1042-1048
14. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456-65
15. Furukawa K, Okamura N, Tashiro M, Waragai M, Furumoto S, Iwata R, et al. Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: Comparison to FDG-PET. J Neurol 2010; 257: 721-7
16. Harada R, Okamura N, Furumoto S, Tago T, Maruyama M, Higuchi M, et al. Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimerá s disease pathology. Eur J Nucl Med Mol Imaging 2013; 40: 125-32
17. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131 (Pt 6): 1630-45
18. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132 (Pt 5): 1355-65
19. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease -An updated hypothetical model of dynamic biomarkers. Lancet Neurology 2013; 12: 207-16
20. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: A report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the alzheimer's association. J Nucl Med 2013; 54: 476-90
21. Kadir A, Marutle A, Gonzalez D, Scholl M, Almkvist O, Mousavi M, et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. Brain 2011; 134 (Pt 1): 301-17
22. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006; 67: 1575-80
23. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007; 68: 1603-6
24. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-19
25. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005; 25: 10598-606
26. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, et al. The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003; 23: 2086-92
27. Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M, et al. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: A novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 2007; 48: 553-61
28. Kung HF, Choi SR, Qu W, Zhang W, Skovronsky D. 18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: A miniperspective. J Med Chem 2010; 53: 933-41
29. Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-beta imaging with Pittsburgh compound B and Florbetapir: Comparing radiotracers and Quantification Methods. J Nucl Med 2013; 54: 70-7
30. Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Nagren K, et al. Assessment of beta-Amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008; 65: 1304-9
31. Leinonen V, Rinne JO, Virtanen KA, Eskola O, Rummukainen J, Huttunen J, et al. Postitron emission tomography with [(18)F]flumetamol and [(11) C] PIB for in vivo detection cerebral cortical amyloid in normal pressure hydrocephalus patients. Eur J Neurol 2013, doi: 10.1111/ene.12102
32. Lilja AM, Porras O, Storelli E, Nordberg A, Marutle A. Functional interactions of fibrillar and oligomeric amyloid-b with alpha7 nicotinic receptors in Alzheimer's disease. Journal of ALzheimer's disease 2011; 23: 335-47
33. Lockhart A, Ye L, Judd DB, Merritt AT, Lowe PN, Morgenstern JL, et al. Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-Amyloid peptide fibrils. J Biol Chem 2005; 280: 7677-84
34. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-9
35. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-52
36. Moghbel MC, Saboury B, Basu S, Metzler SD, Torigian DA, Langstrom B, et al. Amyloid-beta imaging with PET in Alzheimer's disease: Is it feasible with current radiotracers and technologies? Eur J Nucl Med Mol Imaging 2012; 39: 202-8
37. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010; 67: 122-31
38. Nelissen N, Van Laere K, Thurfjell L, et al. Phase I study of the PIB derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer's disease. J Nucl Med 2009; 50: 1251-9
39. Ni R, Marutle A, Nordberg A. Modulation of alpha7 nicotinic acetylcholine receptor and fibrillar amyloid-beta interactions in Alzheimer's Disease Brain. J Alzheimers Dis 2013; 33: 841-51
40. Nordberg A, Rinne JO, Kadir A, Langstrom B. The use of PET in Alzheimer disease. Nat Rev Neurol 2010; 6: 78-87
41. Nordberg A. Molecular imaging in Alzheimer's disease: New perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther 2011; 3: 34
42. Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2013; 40: 104-14
43. Nyberg S, Jonhagen ME, Cselenyi Z, Halldin C, Julin P, Olsson H, et al. Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184. Eur J Nucl Med Mol Imaging 2009; 36: 1859-63
44. Petric A, Johnson SA, Pham HV, Li Y, Ceh S, Golobic A, et al. Dicyanovinylnaphthalenes for neuroimaging of amyloids and relationships of electronic structures and geometries to binding affinities. Proc Natl Acad Sci U S A 2012; 109: 16492-7
45. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al. Betaamyloid imaging and memory in non-Demented individuals: Evidence for preclinical Alzheimer's disease. Brain 2007; 130 (Pt 11): 2837-44
46. Price JL, Morris JC. Tangles and plaques in nondemented aging and" preclinical" Alzheimer's disease. Ann Neurol 1999; 45: 358-68
47. Raman EP, Takeda T, Klimov DK. Molecular dynamics simulations of Ibuprofen binding to Abeta peptides. Biophys J 2009; 97: 2070-9
48. Reiman EM, Jagust WJ. Brain imaging in the study of Alzheimer's disease. Neuroimage 2012; 61: 505-16
49. Rodrigue KM, Kennedy KM, Devous MD Sr, Rieck JR, Hebrank AC, Diaz-Arrastia R, et al. beta-Amyloid burden in healthy aging: Regional distribution and cognitive consequences. Neurology 2012; 78: 387-95
50. Rosenberg PB, Wong DF, Edell SL, Ross JS, Joshi AD, Brasic JR, et al. Cognition and amyloid load in Alzheimer disease imaged with florbetapir F18 (AV-45) positron emission tomography. Am J Ger Psychiatry 2013; 21: 272-8
51. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism. Lancet Neurol 2008; 7: 129-35
52. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31: 1275-83
53. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-Amyloid burden in aging and dementia. Neurology 2007; 68: 1718-25
54. Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med 2011; 52: 1733-40
55. Selkoe DJ. Preventing Alzheimer's disease. Science 2012; 337: 1488-92
56. Shao H, Okamura N, Sugi K, Furumoto S, Furukawa K, Tashiro M, et al. Voxel-based analysis of amyloid positron emission tomography probe [C]BF-227 uptake in mild cognitive impairment and alzheimer's disease. Dement Geriatr Cogn Disord 2010; 30: 101-11
57. Shin J, Lee SY, Kim SH, Kim YB, Cho SJ. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Neuroimage 2008; 43: 236-44
58. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-Amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002; 10: 24-35
59. Sojkova J, Driscoll I, Iacono D, Zhou Y, Codispoti KE, Kraut MA, et al. In vivo fibrillar beta-Amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol 2011; 68: 232-40
60. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-92
61. Thompson PW, Ye L, Morgenstern JL, Sue L, Beach TG, Judd DJ, et al. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J Neurochem 2009; 109: 623-30
62. Tolboom N, Yaqub M, van der Flier WM, Boellaard R, Luurtsema G, Windhorst AD, et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J Nucl Med 2009; 50: 191-7
63. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol 2010; 68: 319-29
64. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, et al. In-vivo imaging of Alzheimer disease beta-Amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 2004; 12: 584-95
65. Villain N, Chetelat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: A voxelwise PiB-PET longitudinal study. Brain 2012; 135 (Pt 7): 2126-39
66. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Australian Imaging Biomarkers and Lifestyle (AIBL) Resarch Group. Amyloid ß deposition, neurodegeration, and cognitive decline in sporadic Alzheimerá s disease: A prospective cohort study. Lancet Neurol 2013; 12: 357-67
67. Villemagne VL, Klunk WE, Mathis CA, Rowe CC, Brooks DJ, Hyman BT, et al. Abeta Imaging: Feasible, pertinent, and vital to progress in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012a; 39: 209-19
68. Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O'Keefe G, et al. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012b; 39: 983-9.
69. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011; 69: 181-92
70. Wolk DA, Grachev ID, Buckley C, Kazi H, Grady MS, Trojanowski JQ, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 2011; 68: 1398-403.
71. Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer's disease: Comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry 2012; 83: 923-6
72. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010; 51: 913-20
73. Wu C, Bowers MT, Shea JE. On the origin of the stronger binding of PIB over thioflavin T to protofibrils of the Alzheimer amyloid-beta peptide: A molecular dynamics study. Biophys J 2011; 100: 1316-24
74. Ye L, Morgenstern JL, Gee AD, Hong G, Brown J, Lockhart A. Delineation of positron emission tomography imaging agent binding sites on beta-Amyloid peptide fibrils. J Biol Chem 2005; 280: 23599-604
75. Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF. F-18 stilbenes as PET imaging agents for detecting beta-Amyloid plaques in the brain. J Med Chem 2005; 48: 5980-8